This study is testing whether CBD Oral (cannabidiol, a compound from the cannabis plant) can affect breast cancer primary tumors. Researchers want to see if CBD Oral, given at 175mg or 350mg twice daily, can reduce cancer cell growth (proliferation) and increase cancer cell death (apoptosis) before surgery. You could be eligible if you are an adult woman (18 or older) with newly diagnosed invasive breast cancer (stages I, II, or III) and a specific measure of cell growth (Ki67 proliferation rate) of 10% or higher. The study is currently unclear on its recruitment status and plans to enroll up to 84 patients.

Study design

This is a randomized, placebo-controlled, partially blinded study. Up to 84 patients will be randomly assigned to receive either CBD Oral or a placebo (an inactive substance).

What's involved

You would take CBD Oral or a placebo twice daily for 5 to 56 days before your scheduled surgery.

Compensation

Not stated in the trial record.

Follow-up

The study will measure the effects of CBD on cell proliferation and apoptosis at 2 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.